Enhanced production and extracellular deposition of the endothelial- type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-beta by unknown
Enhanced Production and Extracellular Deposition of the 
Endothelial-type Plasminogen Activator Inhibitor in 
Cultured Human Lung Fibroblasts by Transforming Growth Factor-fl 
Marikki Laiho,* OUi Saksela,* Peter A. Andreasen,~ and Jorma Keski-Oja* 
* Department of Virology, University of Helsinki, Haartmaninkatu 3, 00290 Helsinki, Finland; 
~Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, 2100 Copenhagen, Denmark. Dr. Saksela's present address is 
Department of  Cell Biology, New York University, 550 First Avenue, New York 10016. Dr. Keski-Oja's present address is 
Department of  Cell Biology, Vanderbilt University, School of  Medicine, Nashville, Tennessee 37232. 
Abstract.  Cultured human embryonic lung fibroblasts 
were used as a model to study the effects of transform- 
ing growth factor-13 (TGFI3)  on the plasminogen activa- 
tor (PA)  activity released by nontumorigenic cells into 
the culture medium. The cells were exposed to TGFfl 
under serum-free conditions, and the changes in PA 
activity and protein metabolism were analyzed by 
caseinolysis-in-agar assays, zymography, and polypep- 
tide analysis. Treatment of the cells with TGFI~ caused 
a  significant decrease in the PA activity of the culture 
medium as analyzed by the caseinolysis-in-agar assays. 
The quantitatively most prominent effect of TGFI3 on 
confluent cultures of ceils was the induction of an Mr 
47,000 protein, as detected by metabolic labeling. The 
Mr 47,000 protein was a  PA inhibitor as judged by re- 
verse zymography. It was antigenically related to a  PA 
inhibitor secreted by HT-1080 tumor cells as demon- 
strated with monoclonal antibodies. The induced Mr 
47,000 inhibitor was deposited into the growth substra- 
tum of the cells, as detected by metabolic labeling, im- 
munoblotting analysis, and reverse zymography assays 
of extracellular matrix preparations.  TGFI3 also de- 
creased the amounts of urokinase-type and tissue-type 
PAs accumulated in the conditioned medium, as de- 
tected by zymography. Epidermal growth factor an- 
tagonized the inhibitory effects of TGFI3 by enhancing 
the amounts of the PAs.  These results indicate that 
growth factors modulate the proteolytic balance of cul- 
tured ceils by altering the amounts of PAs and their 
inhibitors. 
ROWTh factors and their receptors  appear  to be of 
importance  in  different forms of cancer  (14, 49). 
Transforming growth factors (TGFs) t are of particu- 
lar interest because they are able to reversibly induce in non- 
malignant fibroblastic cells properties that resemble those 
observed in cancer cells (cf. reference 14). The two types of 
TGFs, TGFa and TGFI3, have been purified and character- 
ized from both human and rodent sources (4; cf. references 
14, 22).  TGF~ is present in most normal tissues and is pro- 
duced by several types of normal and malignant cells (10, 
36-38). It has been found, for example, in placenta (13) and 
platelets (6, 8). TGFI~ is a bifunctional regulator of cellular 
growth (30, 39). Alone it inhibits the growth of several types 
of malignant cells in soft agar, but it is also the major effector 
that can induce nonmalignant fibroblastic cells to grow in 
soft agar,  either alone (30) or in the presence of epidermal 
growth factor (EGF) or TGFa (36).  TGFI3 appears to regu- 
1. Abbreviations used in this paper: EGF, epidermal growth factor; e-PAl, 
endothelial cell type plasminogen activator inhibitor; PA, plasminogen acti- 
vator;  PAl,  plasminogen  activator inhibitor; TGFI~, transforming  growth 
factor-13; t-PA and u-PA, tissue-type and urokinase-type  plasminogen activa- 
tors,  respectively. 
late the affinity of EGF receptors in NRK cells (5, 29). The 
dual role of TGF~ in the regulation of malignant growth im- 
plicates that there may be other factors that target its action. 
Plasminogen activators (PAs) are  enzymes that activate 
the proenzyme plasminogen into active plasmin,  a  wide- 
spectrum proteinase. Two types of PAs exist: the tissue-type 
and urokinase-type PAs (t-PA and u-PA, respectively) (cf. 
references 9, 41). The production of PA activity has been sug- 
gested to have a  role in tissue destruction in normal and 
pathological conditions, including cancer (cf. reference 9). 
The PAs are secreted as proactivators with little or no activity 
(2, 32, 48, 55).  At least in the case of u-PA, most of the en- 
zyme is in the proactivator form also in vivo (23, 47). The 
proteolytic conversion of the proenzymes to the active en- 
zymes is catalyzed by plasmin in vitro (2, 32, 48, 55), but 
the initial mechanism of the conversion in vivo is unknown. 
The positive feedback regulation by plasmin is effectively 
controlled by specific inhibitors of PAs preventing the activa- 
tion of plasminogen. 
Several  cell  lines  in  culture  secrete  inhibitors  of PAs 
(PAls).  At least three immunologically different types of in- 
hibitors seem to exist: the endothelial cell type of PA inhibi- 
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I) (44, 45), and the placental PAl (6a). Simultaneous secre- 
tion of PAs and PAls can easily lead to misinterpretations of 
the PA activity secreted by the cells, especially when PAs 
have been quantitated using activity measurements only (cf. 
reference 41).  The effects of PAls  have been neglected in 
several studies describing PA activity of cultured cells or PA 
activity found in tissues. 
We have analyzed here the effects of TGFI3 on the PA ac- 
tivity of PA-producing human embryonic lung fibroblasts. 
These cells,  upon exposure to TGFIS, produced enhanced 
amounts of a  PAl  into their medium in a time- and dose- 
dependent manner and also deposited it to their growth sub- 
stratum. TGFI5 also appeared to decrease the secretion of PA 
activity into the medium. Our results indicate that a major 
effect of TGFI5 on cultured embryonic lung fibroblasts is the 
enhancement of e-PAl production. 
This work was presented in part at the UCLA Symposium 
on Growth Factors, Tumor Promoters, and Cancer Genes, 
Steamboat Springs, CO,  April 6-13,  1986 (20). 
Materials and Methods 
Growth Factors and Reagents 
The reagents were obtained from the following sources. TGFfl was a kind 
gift  from  Drs.  A.  Roberts  and  R.  Assoian (National  Cancer  Institute, 
Bethesda, MD). Its purification and properties were as described in detail 
(6).  It  stimulated the growth of NRK cells (clone 49F)  and inhibited the 
growth of A549 lung cancer cells in soft agar as described (30, 39).  EGF 
was purchased from Sigma Chemical Co.  (St.  Louis, MO). 
Urokinase (60,000  IU/mg; Mr 54,000) was purchased from Calbiochem- 
Behring Corp. (La Jolla, CA) and plasminogen and plasmin were from Kabi 
Vitrum (Stockholm,  Sweden).  Aprotinin  (Trasylol) was purchased from 
Bayer (Leverkusen, FRG).  Antibodies to urokinase-type PA (u-PA) were 
produced in rabbits using the above Mr 54,000 u-PA as immunogen as de- 
scribed earlier  (42).  Tissue-type PA and rabbit  polyclonal antibodies to 
tissue-type PA (t-PA)  were a  kind gift from Dr.  D.  Collen (University of 
Leuwen, Belgium) (35). Anti-u-PA and anti-t-PA antibodies did not cross- 
react with each other. Polyclonal and monoclonal antibodies against endo- 
thelial cell  type PAl,  secreted by dexamethasone-treated HT-1080 tumor 
cells, were produced as described (3,  31). 
Cell Cultures 
Human embryonic lung fibroblasls (HEL-299 and WI-38) were obtained 
from American Type Culture Collection  (ATCC CCL-137 and CCL-75, 
respectively). The two other WI-38 cell  lines tested were obtained from 
Flow Laboratories, Inc. (Irvine, UK) and from Dr. A. Vaheri (Department 
of Virology, University of Helsinki, Finland). The cells were cultivated in 
plastic Linbro wells (16-ram diameter, Flow Laboratories, Inc.) and seeded 
at  a  density of  1  ×  104 cells/well  in  medium  199 containing  10%  FCS 
(Gibco,  Paisley,  UK),  100 IU/ml penicillin, and 50  p.g/ml streptomycin. 
Upon  confluency,  4-7  d  later,  the  cells  were  washed  with  serum-free 
medium 199 and incubated under serum-free conditions at 37°C for 8 h be- 
fore the growth factors were added. 
At the onset of the experiment the medium was changed, replaced with 
new serum-free medium supplemented with the growth factors as indicated, 
and incubated for 48 h. The medium was then collected and centrifuged at 
800 g  for  10 min. 
Radioactive Labeling 
Confluent  cultures  of cells  were  washed  and  incubated  in  serum-free 
medium for 6-12 h  before the assay. The medium was changed and the 
cultures were  labeled  with  50  laCi/ml  [35S]methionine  (1,390 Ci/mmol; 
Amersham, UK) in the presence or absence of 2 ng/ml TGFI3 at 37°C for 
4-24 h. The medium was collected and clarified by centrifugation, l-ml ali- 
quots of the medium were precipitated using TCA (final concentration 5 %) 
or incubated with 50-111 aliquots of 50%  (vol/vol) heparin-, concanavalin 
A-, protein A-, gelatin-, or plain Sepharose (Pharmacia Fine Chemicals, 
Uppsala, Sweden) in a rotatory shaker at 4°C for 2 h as described in detail 
(21). The TCA precipitates were washed twice with ice-cold acteone, dried, 
and dissolved in Laemmli's sample buffer (containing 10% 2-mercaptoetha- 
nol)  (25).  The  Sepharose particles  were  washed four times with  PBS/ 
Tween-80 (0.01%) and the bound proteins were dissolved in Laemmli's sam- 
ple buffer. The samples were analyzed by 8% discontinuous SDS PAGE un- 
der reducing conditions (25).  The radiolabeled  molecular mass markers 
(Amersham) used were myosin (Mr 200,000),  phosphorylase b (Mr 92,500), 
BSA (Mr 69,000), ovalbumin (Mr 46,000), carbonic anhydrase (Mr 30,000), 
and lysozyme (Mr 14,300). 
Immunoprecipitation and Immunoblotting Analysis 
with Anti-e-PAI Antibodies 
Medium samples (l ml) from cultures incubated in the presence or absence 
of TGFI3 were preadsorbed with 100 t.tl 50% (vol/vol) protein A-Sepharose 
at 4°C for 2 h. After centrifugation the media were collected and 10 p.g of 
mouse monoclonal IgG for hybridoma clone 1 (31) or normal mouse IgG 
were added together with 50 I.tl of new protein A-Sepharose. The media 
were then incubated in a rotatory shaker at 4°C for 4 h. The antigen-anti- 
body complexes bound to protein A-Sepharose were collected by centrifu- 
gation and washed three times with l0 mM Tris-HCl buffer, pH 7.5, contain- 
ing 0.5 % Triton X-100, 0.1% SDS, and 0.5 % sodium deoxycholate, and once 
with PBS.  The precipitated proteins were dissolved in Laemmli's sample 
buffer, treated at 95°C for 2  min and analyzed by 8%  SDS PAGE under 
reducing conditions. Immunoblotting analysis of proteins was performed 
using immunoperoxidase staining as described (52). 
Immunoaffinity Chromatography 
Monoclonal anti-e-PAI IgG from hybridoma clone  1 or monoclonal IgG 
against the trinitrophenyl group (31) was coupled to cyanogen bromide-acti- 
vated Sepharose 4  B  (32).  l-ml columns containing ,x,1 mg of IgG were 
packed and equilibrated in PBS.  Conditioned culture media were passed 
twice over the columns, and analyzed for PAl activity by reverse fibrin- 
agarose zymography (see below). 
Analysis of  Substratum-attached Material 
WI-38 cells were grown to confluency on plastic Nunclon tissue culture 
dishes (35-mm diameter, Nunc, Roskilde, Denmark). The cultures were ra- 
diolabeled with 50 ~Ci/ml [35S]methionine  for 24 h and the medium was 
removed. The cell-free growth substratum-attached material was analyzed 
as follows. The cultures were washed rapidly with PBS followed by extrac- 
tion of the cells three times at 0°C for 5-min periods with 10 mM Tris-HCl 
buffer, pH 8.0, containing 0.5 % sodium deoxycholate and  l  mM phenyl- 
methylsulfonyl fluoride (PMSF) followed by two washes with 2 mM Tris- 
HC1 buffer, pH 8.0 (16). The proteins were extracted with Laemmli's sample 
buffer and analyzed by 8 % SDS PAGE. The procedure results in a reproduc- 
ible pattern of polypeptides, most of which have been identified as pericellu- 
lar matrix proteins (16, 19). 
Caseinolysis-in-agar and Zymography Assays 
The assays for the demonstration of the total  PA activity were performed 
using agarose plates containing plasminogen and casein (40). Plasminogen, 
when activated by PA present in the medium sample, degrades casein and 
forms a clear disc of caseinolysis in the gel during the sample diffusion, 
proportional  to the PA activity of the sample and time of diffusion. The 
caseinolysis was measured by 24  h,  during which time no background 
caseinolysis due to other proteinases was observed. In control, plates with- 
out added plasminogen were included. Human urokinase was used as a stan- 
dard, and PA activity was plotted in international units (from  100 to 0.01 
IU/ml). 
Zymography was used to identify the molecular weights of either the PAs 
or the PAI.  To detect the molecular forms of PA, the nonreduced medium 
samples collected in the presence of aprotinin (200 IU/ml) were first elec- 
trophoresed in SDS polyacrylamide gels. SDS was removed by extensive 
washing (3  ×  200 ml, 4  h) with PBS/Triton  X-100 (2.5%),  followed by 
casein-agarose zymography as described earlier (15). The PAls were de- 
tected from reduced or nonreduced medium samples using reverse casein- 
agarose (12) or fibrin-agarose (3) zymography. For reverse casein-agarose 
zymography, the samples were analyzed by 8% SDS PAGE under reducing 
conditions, and the polyacrylamide gels were washed and incubated in 200 
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Figure 1. Effect of TGF~ on the PA activity of cultured lung fibro- 
blasts. WI-38 cells (solid circles) and HEL-299 cells (open circles) 
were  cultivated  in  plastic  Linbro  tissue  culture  dishes.  Upon 
confluency the cells were washed two times with medium 199 and 
incubated  in serum-free  medium 199 for 8 h.  The medium  was 
changed,  TGFI3 was added as shown, and the cultures  were in- 
cubated for 48 h. The media were collected and the PA activity was 
determined by caseinolysis-in-agar assays. PA activity is plotted in 
international  units (IU/ml)  in a half-logarithmic scale. 
ml of PBS/Triton X-100 (2.5%) containing 0.5 IU/ml urokinase at 22°C for 
30 min. The polyacrylamide gel was placed on a casein-agarose gel contain- 
ing plasminogen.  For reverse fibrin-agarose zyrnography, washed poly- 
acrylamide gels were layered over agarose gels containing fibrin, plasmino- 
gen, and u-PA (see reference 3).  In both cases, the positions of PAIs were 
revealed by opaque, lysis-resistant zones. 
Results 
TGF~ Decreases the PA Activity 
Cultures  of WI-38  and  HEL-299  human  lung  fibroblasts 
were  grown  to  confluency  and  exposed  to  TGFI3  under 
Figure 2.  Effect of cycloheximide on the TGF~induced PAls and 
on PA activity  of WI-38 cells.  Cycloheximide  (0-10 I.tg/ml) was 
added to confluent cultures of cells in the presence or absence of 
TGFI3 (2 ng/ml) under serum-free conditions. The cultures were in- 
cubated for 48 h, the media were collected,  and their PA activity 
was determined by caseinolysis-in-agar assays. The secreted net PA 
activity  is shown as columns.  No toxic effects of cycloheximide 
were observed during the cultivation. 
Figure 3. Analysis of PA activity secreted by WI-38 cells by zymog- 
raphy, 50 Ixl of conditioned serum-free medium (lanes 3, 5, and 7), 
u-PA (2 ng) (lanes I  and 4), and t-PA (5 ng) (lanes 2 and 6) were 
analyzed by 8 % SDS PAGE followed by casein-agarose zymogra- 
phy for visualization of the enzyme activities. The casein-agarose 
gels used contained antibodies as follows: (A) no additions;  (B) 
anti-t-PA  antibodies  (10  ~tg/ml); (C)  anti-u-PA  antibodies  (10 
I.tg/ml). 
serum-free conditions. After the incubation, the culture me- 
dia were collected and their PA activity was quantitated and 
characterized using the caseinolysis-in-agar assays and zy- 
mography. 
When the WI-38 and HEL-299 cells were cultivated in the 
presence of TGF[~, the net PA activity of the medium was de- 
creased in both cell lines as shown by caseinolysis-in-agar 
assays (Fig.  1).  The inhibitory effect of TGF[~ could be de- 
tected ~10 h after the addition of the growth factor (data not 
shown). Both cell strains tested responded to TGFI3 in a simi- 
lar way. The inhibition could be abolished by adding cyclo- 
heximide (10 Ixg/ml) to the culture medium during the incu- 
bation (Fig. 2). No toxic effects on the cell morphology were 
seen at the cycloheximide concentrations used.  Negligible 
amounts of non-PA proteolytic activity were seen in the cul- 
ture media as  shown by caseinolysis plates without added 
plasminogen (data not shown). The TGFI3 preparation itself 
did not exhibit any proteolytic or protease inhibiting activity 
in the assays. 
WI-38 cells secreted both u-PA and t-PA, as shown by the 
mobility in SDS PAGE followed by casein-agarose zymogra- 
phy for the detection of the activators (Fig. 3 A, lane 3), as 
well as by inhibition of caseinolysis by specific antibodies 
against u-PA and t-PA in the zymography (Fig. 3, B and C). 
WI-38 cells obtained from two other sources as well as HEL- 
299 cells produced also both u-PA and t-PA (gels not shown). 
When medium from WI-38 cells incubated in the presence 
of TGFI3 was analyzed,  a  decrease in the area of the lysis 
zones caused by t-PA and u-PA in casein-agarose zymogra- 
phy was observed, in the case of t-PA below detection limit 
(Fig. 4 A). Concomitantly, a PAl became detectable by re- 
verse fibrin-agarose zymography (Fig.  4  B). 
In other cell types producing both t-PA and inhibitors,  a 
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cells,  as detected by zymographies. Culture conditions  were those 
described in the legend to Fig.  1; the cells  were cultured with  or 
without TGFI3 (1 ng/ml),  as indicated.  Conditioned serum-free cul- 
ture media (40-I.tl aliquots) were analyzed by SDS PAGE, followed 
by casein-agarose zymography to reveal PA activity  (A), or by re- 
verse fibrin-agarose zymography to reveal  PAI activity  (B).  The 
positions of u-PA and t-PA are indicated to the left, and the position 
of a PAl to the right. 
lysis zone of Mr '~100,000 composed of a complex between 
t-PA and the inhibitors is usually detected by zymography (1, 
28, 33, 50). No such lysis zone appeared in the medium from 
TGFI3-treated cells,  and only very low amounts in medium 
from  control  ceils,  which  only  became  detectable  after 
prolonged incubation times (data not shown). On the other 
hand, u-PA is usually present in conditioned culture media 
in the proenzyme form, which does not react with inhibitors 
(3, 46, 54). Thus, the decrease in u-PA and t-PA activity de- 
tectable by zymography does not seem to be due to the com- 
plex formation between the PAs and the inhibitor. 
Our results thus suggest that the decrease in the net PA ac- 
tivity,  as  measured  by  the  caseinolysis-in-agar  assay,  is 
Figure 6.  TGFI3 induces e-PAI 
in cultured  WI-38 human lung 
fibroblasts.  Confluent  cultures 
of cells were grown in the pres- 
ence  or  absence  of TGFI3 (2 
ng/ml),  as described in Materi- 
als  and  Methods.  The  condi- 
tioned culture media were passed 
twice over a column with mono- 
clonal IgG against  the trinitro- 
phenyl group (lanes 1 and 2) or 
monoclonal anti-e-PAl (lanes 3 
and 4), as described in Materi- 
als and Methods.  Aliquots corresponding to 0.1  ml of undiluted 
conditioned culture medium was subjected to SDS PAGE. The gel 
was analyzed by reverse  fibrin-agarose zymography to reveal the 
PAl activity  in the gel. 
caused by decreases in the amounts of u-PA and t-PA as well 
as by an increase in the amount of the inhibitor. 
Characterization of  the Plasminogen Activator 
Inhibitor Induced by TGFB 
Radiolabeling experiments were carried out to examine the 
molecular forms of the TGFI3-induced proteins. WI-38 cells 
were  incubated  with  TGFI3 and  labeled  with  [35S]methio- 
nine  for  24  h  under  serum-free  conditions.  The  secreted 
polypeptides were analyzed by SDS PAGE after precipitation 
with TCA or adsorption to Sepharose conjugates. The pres- 
ence of TGFI3 during the incubation led to strong labeling of 
an Mr 47,000 protein (Fig. 5, lane 1).  This protein bound to 
both concanavalin A- and heparin-Sepharose  (Fig.  5,  lane 
3), and also to some extent to gelatin-, protein A-, and plain 
4B-Sepharose particles (gels not shown) (see reference 21). 
Most of the radioactivity at Mr 47,000 was immunoprecipi- 
tated with a monoclonal antibody against a PAI secreted by 
dexamethasone-treated HT-1080 tumor cells (Fig. 5, lane 4). 
Figure 5.  Effect of TGFfl on the 
polypeptide synthesis of cultured 
WI-38  human  lung  fibroblasts. 
Confluent  cultures  of cells  were 
labeled  with  [35S]methionine in 
the presence of TGFI3 (2 ng/ml) 
under  serum-free  conditions  as 
described in Materials  and Meth- 
ods. The radiolabeled  proteins  of 
the media were isolated and ana- 
lyzed by SDS PAGE followed by 
autoradiography.  (Lane 1) TCA- 
precipitated  conditioned  media; 
(lane  2)  concanavalin  A-Sepha- 
rose-bound proteins; (lane 3) hep- 
arin-Sepharose-bound  proteins; 
(lane 4) immunoprecipitates  with 
monoclonal e-PAl antibody; (lane 
5) immunoprecipitates  with unre- 
lated antiserum.  Medium samples 
from TGFl$-treated (+) or control 
(-) cultures  are indicated  at the 
top of  the figure. The migration of 
fibronectin (FN) and e-PAl are in- 
dicated  to the right, and the mo- 
lecular mass markers (xl0  -3) are 
shown to the left. 
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stratum of WI-38 cells. (A) Deposition of e-PAI induced by TGFI~ 
WI-38 cells were labeled with [35S]methionine in the presence or 
absence of TGFI3 for 24 h and the substratum-attached  materials 
were prepared.  The preparations  were extracted with Laemmli's 
sample  buffer and  analyzed  by 8%  SDS  PAGE under  reducing 
conditions. The autoradiogram of 8 % SDS PAGE is shown. (B) Im- 
munoblotting  analysis  of the  TGFI3-induced growth  substratum- 
attached materials with polyclonal anti-e-PAl.  (C) Reverse casein- 
agarose zymography assay of growth substratum-attached materials 
induced  by  TGFI~ Substratum-attached  material  from  TGFI3- 
treated (+) or control (-) cultures are indicated at the top of the 
figure. Lines indicate the positions of the Mr 47,000 protein and an 
Mr 70,000 protein.  Molecular mass markers (xl0  -3) are shown to 
the left. 
Furthermore,  the  lysis-resistant  zone  in  reverse  fibrin- 
agarose  zymography was  removed by  passing  the  condi- 
tioned  culture  medium  through  an  affinity  column  with 
monoclonal antibodies  against the  HT-1080 cell  inhibitor, 
but  not  by passing  the  medium through  a  column  with  a 
monoclonal antibody of irrelevant specificity (Fig.  6).  The 
HT-1080 tumor cell secreted inhibitor is immunologically 
related  to  the  PAl  secreted  by  cultured  endothelial  cells 
(e-PAl) (31). 
These findings show that the quantitatively most important 
effect of TGFI3 on WI-38 cells is an increase in the amount 
of e-PAl accumulated in the conditioned culture  medium, 
and that the increase in labeling of Mr 47,000 is almost to- 
tally accounted for by an increased secretion of e-PAl. 
The TGF[3-induced e-PAl Is Deposited to 
the Growth Substratum of WI-38 Cells 
WI-38 cell cultures were radiolabeled with [35S]methionine 
in the presence or absence of TGFI3. Analysis of substratum- 
attached  proteins  by  SDS  PAGE  indicated  that  TGFI~  en- 
hanced significantly the accumulation of an Mr 47,000 pro- 
tein  to  the  growth  substratum  (Fig.  7  A).  The Mr 47,000 
protein  was a  PAl  as judged  from reverse casein-agarose 
zymography (Fig. 7 C), and it could be detected by immuno- 
blotting with polyclonal e-PAl antibodies  (Fig.  7  B).  The 
amount of e-PAl was not increased in the samples obtained 
from the  first extractions of the cell cultures  with  sodium 
deoxycholate (gel not shown), indicating that the cells did not 
contain excess amounts of this protein,  but deposited it to 
their extracellular space. 
Also, the radiolabeling of an Mr 70,000  protein (Fig. 7 A, 
lane 4) was increased in the extracellular material of cells 
cultured in the presence of TGFI3. The nature of this band 
is unknown.  However, the Mr 70,000  protein contained im- 
munoreactive e-PAl as detected by immunoblotting analysis 
with polyclonal antibodies against e-PAl (Fig. 7 B). The ac- 
tual changes in the amounts of total Mr 70,000  protein were 
small, but an increase can be seen also by immunoblotting. 
Antagonistic Effects of TGFJ3 and EGF on 
the PA Activity Secreted by Lung Fibroblasts 
We studied the effects of EGF on PA and PAI activity of cul- 
tured WI-38 lung fibroblasts. We found that EGF enhanced 
the secretion of PA activity into the medium of these cells 
at  nanogram concentrations,  as  shown by caseinolysis-in- 
agar assays (Fig. 8). Zymography of the medium samples in- 
dicated  that both u-PA  and  t-PA activities were enhanced 
(Fig.  8, inset).  Reverse casein-agarose zymography did not 
Figure 8. Effect of EGF on PA activity of WI-38 
cells. The experiment was carried out as described 
in the legend to Fig.  1. The cells were cultured in 
the presence of increasing concentrations of EGF 
and the PA activity was determined by the casein- 
olysis-in-agar assay. PA activity is plotted in inter- 
national  units  (IU/ml)  in  a  linear  scale.  (Inset) 
Casein-agarose  zymography  of  culture  media 
from cells  incubated in the presence  or absence 
of EGF (10 ng/ml).  The zymography was photo- 
graphed after 12 h incubation of the caseinolysis 
gel, at which state the t-PA activity of the control 
culture was not yet visible. 
Laiho et al. Plasminogen Activator  Inhibitor Induced by TGFff  2407 Figure 9. Antagonistic effects of EGF and TGFI3  on PA activity. WI-38 cells were grown to confluency and incubated in the presence of 
TGFI~ and EGF as indicated. The experiment was carried out as in the legend to Fig.  1. (A) Enhancement of PA activity by EGF in the 
presence of TGFI]. The cells were incubated with increasing amounts of EGF and a constant amount of TGFI3 (2 ng/ml) for 48 h.  The 
media were collected and analyzed for the net PA activity by the caseinolysis-in-agar assay. (Inset) Zymography of culture media incubated 
in the presence of  TGFI3 (2 ng/ml) and EGE The EGF concentrations used are shown at the top of  the inset. (B) Inhibition of  EGF-stimulated 
PA activity by TGFI]. The cells were incubated with increasing amounts of TGF[~ and constant amounts of EGF (2 ng/ml) for 48 h. The 
media were collected and the PA activity was determined.  PA activity is plotted in a half-logarithmic scale. (Inset) Zymography of culture 
media incubated in the presence of EGF (2 ng/ml) and TGFI~. The TGFI3 concentrations  used are shown at the top of the inset. 
reveal alterations  in  the  amounts  of e-PAl  levels  (gel  not 
shown).  The effect of EGF on u-PA and t-PA was thus an- 
tagonistic to that of TGFIL 
We then carried out dose-dependency experiments to elu- 
cidate the combined effects of these two growth factors. The 
cells were exposed to constant concentrations of one of them, 
and the concentration of the other was varied (Fig. 9). When 
the cells were incubated  with a  constant amount of TGFI3 
(2  ng/ml)  and  increasing  concentrations  of EGF  (0.01-10 
ng/ml), the reappearance of PA activity into the medium was 
observed as detected by caseinolysis-in-agar assays and zy- 
mography (Fig. 9 A).  Zymography indicated that the effect 
of EGF was directed to the enhancement of u-PA activity 
whereas t-PA remained undetectable (Fig. 9 A, inset).  In re- 
verse casein-agarose zymography, the amount of secreted 
e-PAI remained constant (gel not shown). 
When constant amounts of EGF (2 ng/ml) and increasing 
concentrations  of TGFI3  (0.05-10  ng/ml) were used,  a  de- 
crease of PA activity was not detected in the medium by the 
caseinolysis-in-agar assays unless slightly higher concentra- 
tions of TGFI3 (0.5-10 ng/ml) were used (Fig. 9 B). Interest- 
ingly, zymography showed that TGFI3 was able to decrease 
the t-PA activity more efficiently than that of u-PA (Fig. 9 B, 
inset).  When these same samples were analyzed by reverse 
casein-agarose zymography, an increase in  the amount of 
secreted PAI was detected  (gel not  shown).  The effects of 
EGF and TGFI3 on the net PA activity secreted by WI-38 
cells were thus antagonistic. 
Discussion 
The regulation of proteolysis in cultured cells is affected by 
a variety of hormone-like factors (41). Among them are the 
growth factors, which have several biological effects on the 
phenotype and growth characteristics of various cell types. 
The role of growth factors in the regulation of proteolysis is 
poorly known. In the present paper we show that a predomi- 
nant feature in the cellular protein metabolism of cultured 
human embryonic lung fibroblasts affected by TGFI3 is the 
enhancement of the secretion and growth substratum deposi- 
tion of e-PAI (20). The PAl activity was abolished when cy- 
cloheximide was present during the cultivation,  suggesting 
that new protein synthesis was needed.  The induction was 
demonstrated by the appearance of a lysis-resistant zone in 
reverse zymography, which could be removed by a  mono- 
clonal antibody against e-PAI. The induction of a protein co- 
migrating with e-PAl and reacting with monoclonal antibody 
against e-PAI could be demonstrated by metabolic labeling 
of the cells. In addition, polyclonal antibodies against e-PAl 
reacted with an Mr 47,000 protein from TGFl~-induced cell 
substratum-attached material in immunoblotting. TGFI] also 
decreased the amounts of secreted u-PA and t-PA as observed 
from zymography assays. 
Effects of hormonal factors on inhibitors of PAs have been 
described before. Dexamethasone enhances the production 
of e-PAl  in  cultured  HT-1080  fibrosarcoma cells  (1)  and 
e-PAl has been shown to accumulate extracellularly to the 
substratum  of fibroblasts  and  dexamethasone-treated  HT- 
1080 cells (P611~inen, J., O. Saksela, E.-M. Salonen, P. An- 
dreasen, L. S. Nielsen, K. Dan0, and A. Vaheri, manuscript 
submitted for publication).  We have recently shown,  using 
human skin fibroblasts, that TGFI~ enhances the secretion of 
an unidentified PAl in a similar way as described in this study 
(26).  However,  the  secretion  of pro-u-PA  was  enhanced 
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in the two responsive cell strains examined. We have also 
identified  polypeptide  factors  secreted  by  cultured  8387 
fibrosarcoma cells, which affect cellular PA activity by en- 
hancing the PAl secretion (43). These sarcoma cell-derived 
factors resemble TGFI~, but certain differences suggest that 
the sarcoma factors may not be identical to it (M. Laiho, un- 
published results). Protease nexin has been reported to be in- 
duced in skin fibroblasts by phorbol esters, EGF, and throm- 
bin (11). 
Besides  enhancing  e-PAI,  TGFI3  also  decreased  the 
amounts of u-PA and t-PA accumulated in the media of WI- 
38 cells, as judged from the decreased areas of the lysis zones 
caused by u-PA and t-PA; the decreases in the area of  the lysis 
zones could not be accounted for simply by complex forma- 
tion with the inhibitor. Although the intracellular mechanism 
of this effect is presently unknown,  it is likely that TGFI3 
decreases the biosynthetic rate of u-PA and t-PA. 
Embryonic lung fibroblasts grow as a substratum-attached 
cell layer in culture and secrete high amounts of PA activity 
into their medium. In spite of this, they attach to their sub- 
stratum via proteinase-sensitive fibronectin-collagen matrix 
(16, 19). This may be explained, at least in part, by the secre- 
tion  of effective proteinase inhibitors.  Protease  nexin has 
been suggested to be the primary inhibitor of u-PA in fibro- 
blastic cells (24, 44, 45). It has been shown to inhibit extra- 
cellular matrix destruction of cultured HT-1080 tumor cells 
(7). We cannot exclude the possibility that TGFI~ affected the 
levels of protease nexin (or placental type PAl) in the condi- 
tioned culture medium of WI-38 cells. However, the induc- 
tion of protease nexin (or placental type PAl)  is no major 
effect of TGFI3; most if not all of the increase in the labeling 
of an Mr 47,000 protein is accounted for by an increased 
amount of e-PAl.  The data presented here show that also 
e-PAl binds to heparin, indicating that this characteristic, per 
se, cannot be used to distinguish between e-PAl and protease 
nexin. 
Although EGF has been described to potentiate the effects 
of TGFI3 on the growth of normal cells in soft agar,  their 
effects on the growth of A549 human lung carcinoma cells 
are antagonistic (30, 39). In addition, the receptors of TGFI~ 
interact with the EGF receptors at the membranes of NRK 
cells and evidently regulate their affinity (5, 29). Because of 
a possible relationship between these two receptor systems, 
we studied the effects of EGF on the secretion of PA activity 
from WI-38 cells. We found that the effect of TGFI~ on the 
net PA activity of embryonic lung fibroblasts was  antago- 
nized by EGF, which alone enhanced the secretion of PA ac- 
tivity into the culture medium.  The effect of EGF on the 
secretion of PA activity on this cell line is in agreement with 
the previous results obtained with certain other cell lines (27, 
51). The cellular responses to exogenous growth factors may 
thus vary (18) depending on the amount and specificity of the 
receptors, on the interactions between the receptor systems, 
and on the secretion of endogenous growth factors. 
Malignant transformation has in many cases been found to 
be associated with the production of plasminogen activators. 
Transformation of fibroblastic chicken cells with Rous sar- 
coma virus results in the production of PA (34). The mor- 
phological changes in these cells correlate with the PA activ- 
ity, and synthetic PAIs can be used to block the change (34). 
On  the  other  hand,  malignant  transformation of cultured 
cells is associated with the production of different types of 
growth factors (14, 49).  TGFI3 is evidently responsible for 
the induction of soft agar growth of certain nonmalignant 
cells in the presence of other growth factors like platelet- 
derived growth factor,  EGF,  or TGFa (cf.  reference 22). 
However, TGFI3 seems to have a dual role in the regulation 
of soft agar growth; it inhibits the growth of many epithelial 
and several types of malignant cells in agar and obviously 
does not require other growth factors to elicit this function 
(30,  39). 
The mechanism of the inhibitory activity of TGFI3 on the 
growth of normal epithelial and malignant cells is unclear at 
present. If the stimulatory effect of TGFI3 on the secretion 
of PAls can be extended, it might help to explain the effects 
of TGFI~ on the soft agar growth of malignant cells (30, 39). 
Induction of inhibitors of proteolysis into the microenviron- 
ment of cells and their pericellular deposition may help to 
retain the phenotype of the cells or, alternatively, the inhibi- 
tors themselves could serve as attachment proteins for the 
cells. It has recently been reported that TGFfl enhances the 
production and matrix deposition of fibronectin and procol- 
lagen in certain cell lines (17). The enhanced deposition of 
the PAls into the growth substratum is a novel feature in the 
regulation of extracellular proteolysis and matrix degrada- 
tion.  The proteolytic activity of cells may be regulated by 
TGFI~ during their growth and differentiation, and possibly 
also in tissue repair. 
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